Eurofarma is a fully Brazilian owned multinational pharmaceutical company, recognized since 1972 by the medical community and society at large for promoting access to health and quality of life with affordable, quality and innovative treatments.
With operations in 20 countries in Latin America, and 10 strategically distributed manufacturing plants in Latin America, Eurofarma is a front runner in major pharmaceutical segments including Prescription Drugs, Nonprescription Drugs, OTC, Generic Drugs, Hospital, Bidding, Oncology and Outsourcing Services. The company’s broad portfolio encompasses all medical specialties and is a benchmark for central nervous system, anti-infective and hormonal drugs.
Acknowledged for its pioneering spirit and entrepreneurial savviness since its very beginning, Eurofarma has forged national and international partnerships in different cooperation models including licenses, distribution agreements, provision of services in the production sector, joint ventures and co-development, among others. Its innovation-centered pipeline comprises over 200 projects and expansion plans for key global markets.
In addition to the high investment in R&D to come up with new products, Eurofarma invests in health innovation in a broader sense, from new technologies to optimize our processes to disruptive platforms aimed at new business models. Its commitment to innovation led to the creation of the Eurofarma Synapsis project in 2017, a partnership and incentive model for startups focused on the development of disruptive healthcare technology. In 2019, the company created the 1st EmergeLabs Eurofarma, a program bringing entrepreneurial scientists and the market together to reinforce its commitment to developing the national health and innovation ecosystem.
